Page 137 - 南京医科大学学报自然科学版
P. 137
第43卷第5期 杨 静,杨爱祥,沈 蕾,等. 血清aPLA2Rab评估PLA2R相关膜性肾病患者病情和预后的价值[J].
2023年5月 南京医科大学学报(自然科学版),2023,43(5):714-719 ·719 ·
中系膜区增宽和肾小球C1q沉积与继发性膜性肾病 [8] 郑 娜,汪梅花,安 智. 血清抗磷脂酶A2受体抗体与
相关,而节段硬化、其他免疫球蛋白如IgA、IgM沉积 膜性肾病预后关系研究[J].临床军医杂志,2021,49
于肾小球以及C4沉积于肾小球的意义未明,因此本 (8):942-944
[9] 侯俊英. 抗PLA2R抗体对特发性膜性肾病患者终末期
研究纳入以上病理指标。单因素分析结果提示,性
肾病的预测价值[J].中国中西医结合肾病杂志,2020,
别、起病年龄、收缩压、舒张压、尿蛋白、血清肌酐、
21(1):63-65
尿 NAG、尿 RBP、肾小球 IgA 沉积、肾小球 IgM 沉积
[10] 王媛媛,周 华. 抗磷脂酶 A2 受体抗体与原发性膜性
均为肾功能不全的影响因素,经多因素分析后起病 肾病的临床特征和预后的相关性[J]. 中国医科大学学
年龄、舒张压、尿 RBP、肾小球 IgM 沉积为肾功能不 报,2022,51(2):106-110
全的独立危险因素。肾小球IgA 沉积和IgM 沉积的 [11] LEVEY A S,STEVENS L A,SCHMID C H,et al. A new
意义需要进一步研究。 equation to estimate glomerular filtration rate[J]. Ann In⁃
综上所述,本文进一步证实了PLA2R相关膜性肾 tern Med,2009,150(9):604-612
病患者血清中aPLA2Rab滴度与疾病严重程度以及肾 [12] BECK L H,BONEGIO R G,LAMBEAU G,et al. M⁃type
phospholipase A2 receptor as target antigen in idiopathic
脏预后相关,为以免疫学缓解为治疗目标的新理念提
membranous nephropathy[J]. N Engl J Med,2009,361
供理论支持。然而本研究为单中心回顾性研究,研究
(1):11-21
结果需要在多中心前瞻性研究中进一步证实。 [13] Kidney Disease:Improving Global Outcomes(KDIGO)Glo⁃
[参考文献] merular Diseases Work Group. KDIGO 2021 clinical
practice guideline for the management of glomerular dis⁃
[1] MCGROGAN A,FRANSSEN C F,DE VRIES C S,et al.
eases[J]. Kidney Int,2021,100(4S):S1-S276
The incidence of primary glomerulonephritis worldwide:a
[14] ALSHARHAN L,BECK L H. Membranous nephropathy:
systematic review of the literature[J]. Nephrol Dial Trans⁃
core curriculum 2021[J]. Am J Kidney Dis,2021,77(3):
plant,2011,26(2):414-430
440-453
[2] DE VRIESE A S,GLASSOCK R J,NATH K A,et al. A
[15]BOBART S A,DE VRIESE A S,PAWAR A S,et al. Non⁃
proposal for a serology⁃based approach to membranous ne⁃
invasive diagnosis of primary membranous nephropathy
phropathy[J]. J Am Soc Nephrol,2017,28(2):421-430
using phospholipase A2 receptor antibodies[J]. Kidney
[3] HOFSTRA J M,BECK L H,BECK D M,et al. Anti⁃phos⁃
Int,2019,95(2):429-438
pholipase A(2)receptor antibodies correlate with clinical
[16] RAMACHANDRAN R,KUMAR V,NADA R,et al. Seri⁃
status in idiopathic membranous nephropathy[J]. Clin J
al monitoring of anti⁃PLA2R in initial PLA2R⁃negative
Am Soc Nephrol,2011,6(6):1286-1291
patients with primary membranous nephropathy[J]. Kid⁃
[4] BECH A P,HOFSTRA J M,BRENCHLEY P E,et al. As⁃
ney Int,2015,88(5):1198-1199
sociation of anti⁃PLA(2)R antibodies with outcomes after [17] DAHAN K,DEBIEC H,PLAISIER E,et al. Rituximab for
immunosuppressive therapy in idiopathic membranous ne⁃ severe membranous nephropathy:a 6⁃month trial with ex⁃
phropathy[J]. Clin J Am Soc Nephrol,2014,9(8):1386- tended follow⁃up[J]. J Am Soc Nephrol,2017,28(1):
1392 348-358
[5] HOXHA E,HARENDZA S,PINNSCHMIDT H,et al. [18] RUGGENENTI P,DEBIEC H,RUGGIERO B,et al. Anti⁃
PLA2R antibody levels and clinical outcome in patients phospholipase A2 receptor antibody titer predicts post ⁃
with membranous nephropathy and non ⁃ nephrotic range rituximab outcome of membranous nephropathy[J]. J Am
proteinuria under treatment with inhibitors of the renin ⁃ Soc Nephrol,2015,26(10):2545-2558
angiotensin system[J]. PLoS One,2014,9(10):e110681 [19] HOWMAN A,CHAPMAN T L,LANGDON M M,et al.
[6] KANIGICHERLA D,GUMMADOVA J,MCKENZIE E A, Immunosuppression for progressive membranous nephrop⁃
et al. Anti⁃PLA2R antibodies measured by ELISA predict athy:a UK randomised controlled trial[J]. Lancet,2013,
long ⁃ term outcome in a prevalent population of patients 381(9868):744-751
with idiopathic membranous nephropathy[J]. Kidney Int, [20] SEITZ⁃POLSKI B,DEBIEC H,ROUSSEAU A,et al. Phos⁃
2013,83(5):940-948 pholipase A2 receptor 1 epitope spreading at baseline pre⁃
[7] HOXHA E,THIELE I,ZAHNER G,et al. Phospholipase dicts reduced likelihood of remission of membranous ne⁃
A2 receptor autoantibodies and clinical outcome in pa⁃ phropathy[J]. J Am Soc Nephrol,2018,29(2):401-408
tients with primary membranous nephropathy[J]. J Am [收稿日期] 2023-01-17
Soc Nephrol,2014,25(6):1357-1366 (本文编辑:唐 震)